Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution-Reference-Cited by-同舟云学术

Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution

Published:2024-01-17 Issue:1 Volume:17 Page:
ISSN:2052-3211
Container-title:Journal of Pharmaceutical Policy and Practice
language:en
Short-container-title:Journal of Pharmaceutical Policy and Practice

Author:

Teodoro Maria Inês¹²³^ORCID,Mayer Alexandra¹,da Costa Miranda Ana¹,Nunes Hugo⁴,da Costa Filipa Alves¹²³^ORCID,Lourenço António¹⁵

Affiliation:

1. Unidade de Investigação em Epidemiologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal

2. Research Institute for Medicines (iMED), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal

3. Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health and Science, Almada, Portugal

4. Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal

5. NOVA Medical School, Universidade Nova de Lisboa, Lisboa, Portugal

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/20523211.2023.2296551

Reference34 articles.

1. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma

2. Awareness and current knowledge of breast cancer

3. Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice

4. Assembleia da República. (2017). Law n.º 53/2017 14th of July [Creates and regulates the National Cancer Registry]. Diário da República n.º 135/2017 Série I 2017-07-14 3739–3743.

5. Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper